Weight loss drugs are huge these days, and Eli Lilly (LLY) is leading the pack when it comes to these. However, today’s ...

"We exceeded our first-time guidance by $4 billion." - David Ricks, Chair and CEO, Eli Lilly Q4 Earnings Call Moreover, the company's margin expansion was on show in Q4, with the highest non-GAAP ...

CEO David A. Ricks remains optimistic about Eli Lilly's long-term growth, with several important Phase 3 trials on the horizon that could further boost the company's standing in the industry.

Ore Huiying / Bloomberg / Getty Images Pharmaceutical company Eli Lilly is expected to report ... Chief Executive Officer David Ricks also said in January that the company expects production ...

Thanks to impressive sales growth across multiple therapeutic areas in 2024, Eli Lilly ... sending Lilly’s stock down about 6.5% on the day of the announcement. Lilly’s CEO, David Ricks ...

Thank you for joining us for Eli Lilly and Company's Q4 2024 earnings call. I'm Mike Czapar, senior vice president of investor relations. Joining me on today's call are Dave Ricks, Lilly's chair ...

CEO David Ricks said the company expects to produce 60% more doses of the drugs in the first half of 2025 compared to last year. Eli Lilly (LLY) shares tumbled Tuesday after the drugmaker lowered ...

Eli Lilly forecasts $45 billion in 2024 revenue ... During the conference, David Ricks outlined two reasons for the guidance update: The diabetes GLP market, in December, outperforms the rest ...

Eli Lilly exceeded analyst forecasts for both sales and earnings in Q4 2024. As has been true for a while, sales of GLP-1 drugs Mounjaro and Zepbound drove both sales and earnings growth.

SAN FRANCISCO — Eli Lilly CEO Dave Ricks on Tuesday said he believed the company could find “significant common cause” with the incoming Trump administration, including on issues around ...

We recently published a list of Jim Cramer Discusses These 11 Stocks & President Trump’s Sovereign Wealth Fund.

The latest declines in Eli Lilly's stock price occurred in response to management's presentation at the annual JPMorgan Healthcare conference. On Jan. 14, CEO David Ricks told investors that 2024 ...